Showing results (31-40 of 286) with videos related to

Sort By:
Pageof 29
Cureus|February 19, 2024
A New Rat Study Suggests There May Be a Biologic Explanation for Higher Fentanyl Mortality in Men Than in WomenRobert B Raffa, Joseph V Pergolizzi, Jeanette Mathews, et al.
Expert Opinion on Pharmacotherapy|May 10, 2012
QTc interval prolongation by d-propoxyphene: what about other analgesics?Robert B Raffa, Jeffrey J Burmeister, Ekaterina Yuvasheva, et al.
Current Pharmaceutical Design|July 4, 2012
Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulationsJoseph V Pergolizzi, Robert B Raffa, Jason S Pergolizzi, et al.
Expert Opinion on Drug Delivery|May 10, 2018
What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholdersJoseph V Pergolizzi, Robert Taylor, Jo Ann LeQuang, et al.
Journal of Clinical Pharmacy and Therapeutics|April 29, 2021
Are opioid receptor antagonists adequate for "Opioid" overdose in a changing reality?John F Peppin, Joseph V Pergolizzi, Albert Dahan, et al.
Journal of Clinical Pharmacy and Therapeutics|November 29, 2018
Sunscreen bans: Coral reefs and skin cancerRobert B Raffa, Joseph V Pergolizzi, Robert Taylor, et al.
Journal of Pain Research|February 16, 2018
Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release productJoseph V Pergolizzi, Robert Taylor, Jo Ann LeQuang, et al.
Journal of Clinical Pharmacy and Therapeutics|January 18, 2021
The conundrum of polysubstance overdoseJoseph V Pergolizzi, Albert Dahan, Jo Ann LeQuang, et al.
Journal of Clinical Pharmacy and Therapeutics|August 26, 2018
Discovery of "folded DNA" structures in human cells: Potential drug targetsRobert B Raffa, Joseph V Pergolizzi, Robert Taylor, et al.
Pageof 29